Oral bacteria contributing to bowel disorders

An international team of researchers has found evidence that suggests certain types of oral bacteria may cause or exacerbate bowel disorders. Bowel disorders such as irritable bowel syndrome, ulcerative colitis and Crohn's disease are more than just a nuisance, they can cause serious degradation to quality of life, and in some cases, can even be deadly.

Finding a link between bacteria that live in the mouth and common bowel disorders could show the association between oral bacteria and bowel disorders. Patients with one of the three main types of bowel disorders also had higher than normal levels of oral bacteria in their feces, suggesting higher levels in their guts. Suspecting there may be a link, researchers conducted several experiments to learn more about the connection between the two types of bacteria.

In the first experiment, the researchers introduced human saliva from people with Crohn's disease into the guts of mice with a sterilized gut microbiome. A closer look revealed the bacteria responsible for the inflammation was Klebsiella pneumoniae, a strain commonly found in the human mouth, but seldom in the gut.

In another experiment, the researchers introduced the bacteria directly into the intestines of healthy mice and found it caused no problems. Giving the mice Klebsiella-resistant antibiotics once again caused inflammation when Klebsiella was introduced. Other experiments with saliva from colitis patients offered similar results. There may be a link between the oral bacteria and bowel disorders.
          haleplushearty.blogspot.com

Cyltezo for chronic inflammatory diseases

Cyltezo is for the treatment of multiple chronic inflammatory diseases, including: moderate to severe active rheumatoid arthritis, moderate to severe polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, moderate to severe active adult Crohn’s disease,
moderate to severe active ulcerative colitis and moderate to severe plaque psoriasis

Patients treated with adalimumab products, including Cyltezo, are at increased risk for developing serious infections that may lead to hospitalization or death.

Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease.

Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.

Do not start Cyltezo during an active infection, including localized infections.
Patients older than 65 years, patients with co-morbid conditions and patients taking concomitant immunosuppressants may be at greater risk of infection.

Cyltezo for patients with these disorders; discontinuation of Cyltezo should be considered if any of these disorders develop.
Hematological Reactions
Congestive Heart Failure
Autoimmunity
Patients on Cyltezo should not receive live vaccines.
          haleplushearty.blogspot.com